Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1.1%. By the end of trading, Illumina rose $2.14 (1.5%) to $146.67 on heavy volume. Throughout the day, 4,391,788 shares of Illumina exchanged hands as compared to its average daily volume of 1,477,000 shares. The stock ranged in a price between $140.05-$154.99 after having opened the day at $142.98 as compared to the previous trading day's close of $144.53. Other companies within the Health Care sector that increased today were:

Horizon Pharma



), up 18.2%,




), up 11.2%,

Organovo Holdings



TheStreet Recommends

), up 10.2% and




), up 9.9%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $17.7 billion and is part of the drugs industry. The company has a P/E ratio of 165.0, above the S&P 500 P/E ratio of 17.7. Shares are up 30.7% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the negative front,

Progenics Pharmaceuticals



), down 27.4%,

TearLab Corpoartion



), down 14.1%,

BG Medicine



), down 11.5% and

Idenix Pharmaceuticals



), down 10.4% , were all laggards within the health care sector with




) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.